Introduction {#S5}
============

The transfusion of human blood products, including stored red blood cell units (pRBCs), is necessary for the treatment of hemorrhage and anemia \[[@R1]--[@R4]\]. Compared to fresh units, transfusion of aged pRBCs has been associated with increased rates of pneumonia, sepsis, multi-organ failure, and mortality \[[@R5]--[@R8]\]. The presumed cause of these adverse outcomes is the erythrocyte "storage lesion", which is composed of a vast array of morphological and biochemical changes that occur as erythrocytes age during storage \[[@R9]\]. A particularly deleterious aspect of this lesion is the age-related hemolysis that occurs as erythrocyte structure degrades over time.

During pRBC storage, erythrocyte structural proteins, lipids, and carbohydrates undergo oxidative injury \[[@R10]\] which leads to alterations in membrane structural components \[[@R11]\]. Tyrosine phosphorylation of band 3 protein leads to cross-linking and diffusion from the erythrocyte membrane \[[@R12], [@R13]\]. Phosphatidylserine becomes externalized, and erythrocytes lose membrane domain as well as their classic biconcave disc shape and deformability \[[@R10], [@R12], [@R14]\]. This increased fragility contributes to age-related acidosis and hemolysis as intracellular ions and molecules escape from the cells \[[@R15], [@R16]\].

Sphingolipids are a class of lipids with a backbone of sphingoid bases, and are known to play an important role in the regulation of cell membrane structure and integrity, cell signaling (in particular, cell stress) and apoptosis \[[@R17]--[@R21]\]. Ceramide, a sphingolipid created by the enzyme acid sphingomyelinase (ASM), is known to form microdomains on erythrocyte membranes \[[@R22]\] and has been strongly linked to eryptosis, or suicidal erythrocyte death \[[@R23]--[@R26]\]. Our research has recently shown treatment of pRBCs with amitriptyline prior to storage leads to reduced ASM activity, reduced ceramide concentrations, and decreased lung injury in mice receiving blood transfusions \[[@R27]\], but the associated mechanisms are not fully understood. In the present study, we hypothesized that inhibition of ASM during pRBC storage would reduce storage-related erythrocyte hemolysis.

Materials and Methods {#S6}
=====================

Animal Model {#S7}
------------

Male C57BL/6 mice aged 8--10 weeks were purchased from Jackson Laboratories, fed standard laboratory diet and water ad libitum, and acclimated for 1 week in climate-controlled conditions with 12 hours light-dark cycles prior to use. All experiments were approved by the Institutional Animal Care and Use Committee at the University of Cincinnati.

Blood Banking and Treatment {#S8}
---------------------------

Human pRBCs were purchased from Hoxworth Blood Bank (Cincinnati, OH) and stored at 4°C for 42 days according to standard blood banking practice \[[@R28]\]. These units were leukoreduced by filtration prior to storage as a matter of routine. Murine pRBCs were prepared and stored as previously described \[[@R29]\], and then stored in Eppendorf tubes as 1 mL "units" at 4°C for 14 days. These murine pRBCs were not routinely leukoreduced prior to storage. Where used, amitriptyline and fluoxetine (Sigma-Aldrich, St Louis, MO, USA) were dissolved in normal saline (0.9% sodium chloride) and added to mouse and human pRBCs in a 1:10 dilution prior to storage. Except for dose-response experiments, amitriptyline treatment refers to a 125 μM concentration of amitriptyline in pRBCs. In this manuscript, "aged" refers to 42 days for human pRBCs and 14 days for murine pRBCs.

Our laboratory has an established murine blood banking model that is used for the *in vitro* study of erythrocyte storage as well as *in vivo* transfusion studies of various blood components \[[@R3], [@R29]--[@R31]\]. Due to this experience, the majority of experiments are performed with murine blood rather than human blood. In this study we will demonstrate an effect of ASM inhibition on hemolysis in both human and murine blood and further studies regarding the mechanism of this phenomenon, as well as *in vivo* transfusion, will be performed with murine blood alone.

Blood Component Isolation {#S9}
-------------------------

Erythrocytes were pelleted from pRBC samples at 2,000*g* for 10 minutes at 4°C. The supernatant from this spin was then centrifuged at 10,000*g* for 10 minutes at 4°C to pellet any remaining cells or platelets. Hemoglobin-containing microparticles were pelleted using a 20,000*g* spin for 30 minutes at 4°C \[[@R32]\]. This final cell- and particle-free serum was used to analyze free hemoglobin, a marker of hemolysis.

Erythrocyte Characterization {#S10}
----------------------------

Cell-free hemoglobin was quantified using a Coulter AcT diff Analyzer (Beckman Coulter Corp., Brea, CA). We chose flow cytometry over microscopy to characterize changes to the erythrocyte membrane, as this method requires little manipulation prior to analysis of the cell. While microscopy offers more detailed imaging of the cell membrane, normal blood smears change the membrane shape and require fixation of cells that artificially distorts the membrane. On flow cytometry, erythrocytes were identified using antibodies to glyophorin A: murine cells with PE-conjugated ter-119 \[[@R33]\] and human cells with PE-conjugated CD235a \[[@R34]\]. Forward scatter (FSC) was used as a surrogate to measure erythrocyte size or volume, and side scatter (SSC) was used to estimate membrane complexity or roughness. Phosphatidylserine exposure (FITC-conjugated annexin V \[[@R35]\]), and band 3 protein integrity (eosin-5-maleimide\[[@R36]\]) were analyzed using an Attune flow cytometer (Life Technologies, Carlsbad, CA). Antibodies for ter-119, CD235a, and Annexin V were acquired from BD Biosciences (San Diego, CA), and eosin-5-maleimide was obtained from Life Technologies (Carlsbad, CA).

Effect on Transfusion Recipient {#S11}
-------------------------------

Aged murine pRBCs (after 14 days of storage), with or without amitriptyline treatment, were transfused into healthy recipient mice to study the difference in free hemoglobin in the transfusion recipient. 500μL pRBC was injected via penile vein using a 25 gauge needle under isoflurane anesthesia. 30 minutes after transfusion, recipients were sacrificed and their circulating blood was collected via cardiac puncture. Cells were removed similar to the blood banking process and hemoglobin content was measured in the cell-free serum as above.

Statistical Analysis {#S12}
--------------------

Sample numbers from each experiment are reported in the figure legends. Figures represent mean values and error bars represent standard deviation. One-way ANOVA with post-hoc testing was used to compare means across more than 2 groups and t-tests were used to compare means between two groups. Significance was defined as p-value less than 0.05. All analysis was performed using SigmaPlot (Systat Software, San Jose, CA).

Results {#S13}
=======

Acid Sphingomyelinase Inhibition Reduces Age-Related Hemolysis {#S14}
--------------------------------------------------------------

As hemolysis represents a significant component of the erythrocyte storage lesion, we initially determined the effect of ASM inhibition on hemolysis during pRBC storage. Human ([Fig. 1A](#F1){ref-type="fig"}) and murine ([Fig. 1B](#F1){ref-type="fig"}) pRBCs were treated with increasing doses of amitriptyline, a known ASM inhibitor \[[@R37]\], and we observed a dose-dependent reduction in hemolysis with treatment. Human pRBCs demonstrated the greatest reduction at 50--100 μM. Murine pRBCs demonstrated the greatest effect at 125--250 μM amitriptyline.

In order to determine the time course of free hemoglobin release during erythrocyte storage, we examined murine pRBCs throughout the planned storage period. Our data indicate that pRBC hemolysis tends to occur late during storage, at days 12 and 14 ([Fig. 1C](#F1){ref-type="fig"}). Free hemoglobin release was significantly decreased with amitriptyline treatment at these time points as well ([Fig. 1C](#F1){ref-type="fig"}).

Next, to verify that the reduction in hemolysis that we observed was due to ASM inhibition and not specific to amitriptyline, we treated murine pRBCs with fluoxetine, another functional inhibitor of ASM \[[@R37]\]. Fluoxetine treatment resulted in a significant reduction in hemolysis during pRBC storage ([Fig. 1D](#F1){ref-type="fig"}). These data suggest that acid sphingomyelinase inhibition results in a dose-dependent reduction in hemolysis during pRBC storage.

Acid Sphingomyelinase Inhibition Stabilizes Erythrocyte Membranes during Storage {#S15}
--------------------------------------------------------------------------------

One potential mechanism for decreased erythrocyte hemolysis secondary to amitriptyline treatment is improved stabilization of the cell membrane. In order to examine the effect of amitriptyline treatment on characteristics of the red blood cell membrane, we evaluated these characteristics by flow cytometry. Compared to freshly obtained erythrocytes, aged erythrocytes treated with vehicle (normal saline) demonstrate decreased size and membrane roughness compared to fresh erythrocytes ([Fig. 2A and B](#F2){ref-type="fig"}). Storage of pRBCs with amitriptyline resulted in a dose-dependent preservation of size and roughness, suggesting that ASM inhibition results in membrane stabilization ([Fig. 2A and B](#F2){ref-type="fig"}).

Phosphatidylserine, normally located on the intracellular plasma membrane, is known to become exteriorized during erythrocyte aging and serve as an indicator of senescence \[[@R10]\]. In order to examine the effect of ASM inhibition phosphatidylserine expression, murine pRBCs were stored with or without amitriptyline, labelled with FITC-coupled annexin V, and analyzed by flow cytometry. Phosphatidylserine externalization was nearly undetectable in fresh erythrocytes and sharply increased during pRBC storage ([Fig. 3A](#F3){ref-type="fig"}). Storage of pRBCs with amitriptyline resulted in a dose-dependent reduction in phosphatidylserine externalization ([Fig. 3A](#F3){ref-type="fig"}).

Another well-known aspect of the erythrocyte membrane disruption is altered expression of the key structural protein Band 3 \[[@R12]\]. Flow cytometry analysis demonstrated that a very high proportion of fresh erythrocytes express Band 3 protein, whereas expression is decreased during pRBC storage ([Fig. 3B](#F3){ref-type="fig"}). Storage of pRBCs with amitriptyline reduced Band 3 protein loss by nearly 50%. In summary, these findings suggest that ASM activity in stored pRBCs contributes to changes in erythrocyte size, complexity, and membrane composition, and that inhibition of ASM reduces these age-related changes.

Transfusion of Amitriptyline-Treated pRBCs Reduces Circulating Free Hemoglobin {#S16}
------------------------------------------------------------------------------

After determining that acid sphingomyelinase inhibition prevented hemolysis during pRBC storage, we utilized a murine model of blood transfusion to study the effect on transfusion recipients. Mice received a 500 μL transfusion of either vehicle- or amitriptyline-treated pRBCs after 14 days of storage. Following transfusion, mice receiving pRBCs treated with amitriptyline had significantly less circulating cell-free hemoglobin than mice receiving vehicle-treated pRBCs ([Fig. 4](#F4){ref-type="fig"}). These data suggest that acid sphingomyelinase inhibition during pRBC storage benefits the transfusion recipient by decreasing the burden of free hemoglobin associated with transfusion of aged blood products.

Discussion {#S17}
==========

Our data demonstrate that hemolysis occurs in an age-related fashion during pRBC storage. Inhibition of ASM with amitriptyline results in a dose-dependent reduction in hemolysis in both human and murine pRBCs. Amitriptyline treatment also prevents changes in erythrocyte size and membrane roughness that occur during pRBC storage. Moreover, amitriptyline prevents phosphatidylserine externalization and loss of band 3 protein, two important aspects of the erythrocyte storage lesion. Subsequently, mice transfused amitriptyline-treated pRBCs received a significantly lower burden of free hemoglobin.

Cell-free hemoglobin in transfused pRBCs has been linked with adverse patient outcomes. Not only does free hemoglobin contribute to acute inflammation \[[@R38]\], it also scavenges nitric oxide, which is created by endothelial cells and helps control blood flow by inducing relaxation of vascular smooth muscle \[[@R39], [@R40]\]. This limits endothelial-dependent vasodilation and end organ perfusion \[[@R15], [@R41]--[@R43]\], which has been suggested to adversely affect clinical outcomes \[[@R38], [@R44]--[@R48]\]. Moreover, patients with cancer and other chronic conditions necessitating frequent blood transfusions can demonstrate iron overload and subsequent organ dysfunction over time \[[@R49]\]. As one pRBC contains 220--250mg of iron, transfusion recipients must clear greater than 50mg of iron per pRBC transfused \[[@R50]\]. The ability to reduce this burden of free hemoglobin, as seen in our murine model of blood transfusion, may offer a great opportunity to reduce some of the deleterious consequences of aged pRBC transfusion.

The erythrocyte storage lesion is a broad collection of biochemical and morphological changes that occur as these cells age during pRBC storage. Most of these changes, such as increased lactate and potassium concentrations, are merely descriptive and do not identify mechanisms of erythrocyte breakdown. It was posited that oxidative stress leads to morphological alterations of key structural proteins and lipids such as band 3 protein and phosphatidylserine \[[@R10]--[@R12]\]. Indeed, treatment of erythrocytes with natural antioxidants has been shown to prolong survival and reduce phosphatidylserine exposure \[[@R51]\]. Dinkla et al. \[[@R22]\] have recently shown that incubation of erythrocytes with sphingomyelinase results in the formation of ceramide-enriched platforms, phosphatidylserine exposure, band 3 changes, and CD59 clustering, and that these changes lead to decreased cell size and increased cell fragility. We have shown that inhibition of ASM during pRBC storage prevents these changes, further implicating sphingolipid metabolism as a driver of many important aspects of the erythrocyte storage lesion, including hemolysis. Multiple studies have shown similar findings; treatment of stored blood with a variety of compounds has led to ceramide formation with increased membrane reorganization and eryptosis *in vitro* \[[@R52]--[@R58]\].

ASM has been previously implied in the formation and release of microparticles from erythrocytes \[[@R31], [@R59]\]. Thus, it is important to know whether the measured "cell-free hemoglobin" is microparticle bound versus actually suspended in serum \[[@R60]\]. In order to distinguish the two, we performed multiple centrifugation to identify the fraction containing hemoglobin. Erythrocytes were pelleted first, followed by leukocytes and then platelets. Next, the microparticle-rich supernatant was centrifuged at 20,000*g* for 30 minutes in order to remove microparticles \[[@R32]\]. This microparticle-poor supernatant was used to quantify free hemoglobin as a marker of hemolysis. It is possible that this serum still contained hemoglobin in smaller particles such as exosomes. However, even after centrifugation of up to 100,000*g* for 60 minutes there was still a visible difference in free hemoglobin between units that were and were not treated with amitriptyline (unpublished observations). As such, the authors feel confident that ASM inhibition results in not only reduced microparticle production \[[@R31]\] but also a decrease in the release of free hemoglobin.

The age-related derangements in erythrocyte structure we observed, specifically phosphatidylserine and band 3 protein, are known to contribute to adverse erythrocyte survival after pRBC transfusion \[[@R10], [@R61]\]. Not only does storage result in erythrocytes that are less deformable and less able to pass through capillaries, the externalization of phosphatidylserine contributes to endothelial cell adhesion that may contribute to microangiopathy and tissue damage \[[@R62], [@R63]\]. The role of ASM in these age-related changes is incompletely understood. However, our data indicate that amitriptyline treatment maintains erythrocyte structural integrity by preserving band 3 protein as well as the internalization of phosphatidylserine. While we cannot describe the absolute effect on band 3 concentration, the structure of the protein is preserved with amitriptyline based on the immunoreactivity in our assay. This may potentially explain the decreased hemolysis we observed. These findings provide evidence linking ASM activity in stored erythrocytes with membrane degradation over time.

One concern with the use of amitriptyline as a pRBC additive may be the potential toxicity of transfusing large volumes of pRBCs treated with amitriptyline. Reported toxicity of amitriptyline in animals ranges from 15--30 mg/kg \[[@R64], [@R65]\]. If amitriptyline remained stable during pRBC storage, which is unlikely, this would mean that a 70 kg patient would receive a toxic dose of amitriptyline at doses around 1g. This equates to 25.5 L of blood, or \>100 pRBC bags, treated with 125μM amitriptyline. A patient receiving this volume would likely be actively bleeding, thus losing amitriptyline at the same time it is being transfused and unable to accumulate a toxic dose of the drug. While the potential toxicity of this therapy seems improbable, our lab plans to investigate the pharmacokinetics of amitriptyline in stored pRBCs before taking this therapy to the clinical arena.

In conclusion, we have shown that ASM activity during pRBC storage correlates with known aspects of the erythrocyte storage lesion. Treatment with amitriptyline, an FDA-approved inhibitor of ASM \[[@R66]\], dramatically reduced hemolysis during pRBC storage. Further, we have found that ASM inhibition correlates with preservation of phosphatidylserine and band 3 protein integrity, suggesting a possible mechanism by which ASM activity may contribute to age-related erythrocyte degradation. Combined with recent work from our lab \[[@R31]\], these findings further indicate that sphingolipid metabolism, specifically ASM activity, is a novel target for improving the quality of stored blood products.
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![Inhibition of acid sphingomyelinase reduces hemolysis in stored blood. Amitriptyline treatment dose-dependently reduces hemolysis in stored units of (A) human and (B) murine pRBCs (0 μM represents normal saline vehicle only, values represent fold change in cell-free hemoglobin at the end of storage, mean ± SD, n = 5--7, \**P* \< 0.05 vs 0 μM, ANOVA). (C) Amitriptyline treatment reduces hemolysis that occurs towards the end of murine pRBC storage (solid line = vehicle, dashed line = 125 μM amitriptyline, \**P* \< 0.05 vs amitriptyline, t-test). (D) Fluoxetine treatment also reduced hemolysis in murine pRBCs during storage (mean ± SD, n = 5, \**P* \< 0.01 vs 0 μM, t-test).](nihms920365f1){#F1}

![Inhibition of acid sphingomyelinase prevents age related changes of mouse erythrocytes after 14 days of storage. Erythrocytes (ter-119 positive events) in aged, vehicle-treated pRBCs (0 μM) demonstrate decreased size and complexity on flow cytometry, as indicated by forward scatter (A) and side scatter (B), respectively. Amitriptyline treatment dose-dependently prevented these changes (mean ± SD, n = 5, \* *P* \< 0.05 vs 0 μM, \*\* *P* \< 0.05 vs 0, 50 μM, \*\*\* *P* \< 0.05 vs 0, 50, 125 μM, \*\*\*\* *P* \< 0.05 vs 0, 50, 125, 250 μM).](nihms920365f2){#F2}

![Inhibition of acid sphingomyelinase prevents the age-related membrane structural changes. (A) Amitriptyline treatment reduces phosphatidylserine externalization. Fresh erythrocytes (ter-119 positive events) demonstrate almost no annexin V positivity, whereas aged vehicle-treated (0 μM) show greatly increased positivity. Amitriptyline treatment dose-dependently reduced annexin V positivity (mean ± SD, n = 5, \**P* \< 0.05 vs 0 μM, \*\* *P* \< 0.05 vs 0, 50 μM, \*\*\*\* *P* \< 0.05 vs 0, 50, 125, 250 μM). (B) Acid sphingomyelinase inhibition preserves band 3 protein integrity. Erythrocytes were assayed on flow cytometry for band 3 protein, as measured by eosin-5-maleimide (EMA) positivity. Vehicle-treated aged pRBCs have decreased band 3 protein compared to fresh pRBCs, whereas amitriptyline (AT, 125 μM) treatment preserves band 3 protein (mean ± SD, n = 5, \* *P* \< 0.05 vs vehicle).](nihms920365f3){#F3}

![Acid sphingomyelinase inhibition during pRBC storage reduces circulating free hemoglobin burden in transfusion recipients. Mice that received at 500μL transfusion of pRBCs stored with amitriptyline for 14 days (AT, 125 μM) demonstrated lower levels of circulating free hemoglobin than mice receiving vehicle-treated pRBCs (mean ± SD, n = 4, \* *P* \< 0.05 vs vehicle).](nihms920365f4){#F4}
